

NEWSLETTER

IN THIS ISSUE:

LETTER FROM THE PRESIDENT1
PHYSICIAN ANESTHESIOLOGIST WEEK 2021
PHYSICIAN HIGHLIGHT3
COMMITTEE HIGHLIGHT4
I ITERATURE REVIEW SURVEY 5

JANUARY 2021

FSA Executive Office 786-300-3183 executiveoffice@fsahq.org www.fsahq.org

LETTER FROM THE PRESIDENT

FRANK ROSEMEIER, MD

Dear FSA Members,

Today marks the beginning of seventh annual Physician Anesthesiologists Week, a period during which the vital role of physician anesthesiologists is recognized in leading the anesthesia care team, ensuring the delivery of high-quality care, and keeping patients safe during surgery. Your postsecondary education of 12 of 14 years; up to 16,000 hours of clinical training and subspecialty training in pediatric, cardiothoracic, regional, and neurosurgical anesthesia; labor and delivery; pain management or critical care medicine is unmatched and allows you to respond to moments of crisis quickly and efficiently. You make the difference between life and death in the operating room saving 7 lives per 1000 anesthesia or surgical complications. As experts in peri-operative medicine, you reduce unnecessary testing, same-day cancellations, operating room emergencies and surgical complications enhancing patients' recovery and reduce their hospitals stays.



With the COVID-19 pandemic your expertise and extensive clinical training enabled you to pivot quickly to treating patients in the ICU. You developed protocols to keep the anesthesia care team safe to fight another day and helped to safe-guard critical ill COVID-19 patients undergoing surgical procedures. Just yesterday, I cared for a desperately ill, young man with life-threatening COVID-19 on ECMO. Wearing layers of protective equipment, fine tuning the anesthesia, adjusting vasopressors and volume status, instituting lung protective, ventilatory strategies and performing TEE whilst communicating under the handicap of a N100 mask, I felt honored to be trusted by my surgical colleagues with my skills for keeping the hope of this patient and his family alive. For a brief second, I reflected on my own medical training thanking my teachers and mentors for preparing me for moments like this.

You make a difference every day you step into the OR, every time you lead the anesthesia care team, on each occasion you prescribe the anesthesia plan, whenever you address your patient's comfort. You are the guardian of their safety and "Made For this Moment". For all you do, silently, in the background, almost unnoticed, you make your profession proud and for this and on behalf of the lives you touch I am thankful – to you!

I am grateful for your trust in leading our professional organization. I extend my gratitude to Governor Ron DeSantis who recognized the importance of physician anesthesiologists by proclamation.

Sincerely,

Frank Rosemeier, MD FSA President

PHYSICIAN ANESTHESIOLOGISTS WEEK #PhysAnesWk21

JANUARY 31 - FERUARY 6, 2021

Join ASA for the seventh annual Physician Anesthesiologists Week! Make your voices heard on critical issues; advocate for the specialty and your patients; and let policymakers know the vital role physician anesthesiologists have in delivering high-quality care and keeping patients safe.

This year's event will spotlight how physician anesthesiologists are made for critical moments and uniquely qualified to lead patient care, whether it's managing a crisis during surgery, providing pain management or serving on the front lines of a pandemic.

Read how our
FSA Members are
MADE FOR THIS
MOMENT
Click here.

- Get the resources you need to plan for a successful week of advocacy - visit the ASA webpage.
- → Download the promotional banner to share on your social media visit the FSA WEBSITE




PHYSICIAN HIGHLIGHT

MEET YOUR NEWEST FSAPAC BOARD MEMBER

In December, Dr. Mooed Azam was elected to the FSAPAC Board of Directors. The Current Board is compromised Drs Frank Frank Rosemeier (FSA President), Christian Diez (FSA Past President), Jay Epstein (Legislative Chair), John Doyle and Mooed Azam. Congratulations! Visit the *FSAPAC WEBPAGE*.

Dr. Azam has practiced at AdventHealth Orlando for the past 17 years. He has served as the Director of Liver Transplant Anesthesiology since the program's inception AdventHealth/Florida Hospital over a decade ago, and has in-depth involvement in Patient Blood Management, Regional Anesthesia, and clinical IT. He currently serves on several of his practice's national committees: Clinical Quality Committee, Legislative Committee, and chairs their national PAC board. He has served on the FSA Board of Directors and FSA Legislative Affairs committee. He completed his MBA from the George Washington School of Business, anesthesiology residency training at The Johns Hopkins Hospital, and a medical internship at University of Miami's Jackson Memorial Hospital.





FSA WEBINAR SERIES: BUSINESS OF MEDICINE

The Florida Society of Anesthesiologists will have its series of webinar presentations focused on career planning for residents, fellows and junior faculty interested in working as an Anesthesiologist or one of its subspecialties in the state of Florida. Join the final presentation for a thoughtful and informative discussion on a comprehensive list of subjects relating to you and your career path.

Thursday, Feb. 18, 2021, 6:00pm EST "Anesthesia Fellowships: Tips to get best results."

Moderator: Steven Porter, MD Speakers: Lydia Jorge, MD & Rene Przkora, MD

The webinars are FREE – only Zoom registration is required!

Register today: **CLICK HERE**

COMMITTEE HIGHLIGHT

PROFESSIONAL DIVERSITY COMMITTEE

The FSA Committee on Professional Diversity is seeking to learn more about our members' personal experiences with racial and gender discrimination. We intend to anonymously compile our collective experiences and share them with our leadership and general membership via educational forums as an effort to improve awareness and enhance our commitment to diversity as an organization and as individuals. If you have experiences you would like to share, please follow the link below and fill out the secure form. Please note, your name will not be listed unless it is specifically selected that you would like it shared. Thank you for your time. If you would like more information on this committee, please email lauren@fsahq.org.

SHARE YOUR EXPERIENCE

"The Color of Normal-Racism is a System, Not an Event"

Our very own FSA members, Dr. Keya Locke and Dr. Zachary Deutch, spoke and lead on the topic of "The Color of Normal-Racism is a System, Not an Event" at theVirtual PRACTICE MANAGEMENT™ 2021 meeting. Thank you for our colleagues for leading this important conversation on January 31, 2021. Use the link below to register to hear more about this important topic and see the whole program for Practice Management 2021.





PRACTICE MANAGEMENT 2021

PRACTICE MANAGEMENT. JANUARY 29-31

Would you use Sugammedex in patients with end-stage renal disease?

BRIEF LITERATURE REVIEW

Our FSA members, Steven B. Porter, MD and J. Ross Renew, MD, published a study titled, <u>"Sugammadex use in patients with end-stage renal disease: a historical cohort study,"</u> sparking discussions as sugammadex (SGX) is not approved for use in patients with end-stage renal disease (ESRD).

The original idea for the study was a result of the authors observing the administration of SGX to patients with ESRD at Mayo Clinic in Florida, despite the off-label usage. As such, the authors reviewed the chart of every patient with SRD who had received SGX to antagonize the neuromuscular blockade utilized intraoperatively. This cohort included over 200 patients and is currently the largest study to report on this topic. Keeping in mind, patients who received kidney transplantation were included in this study, which could contribute some confounding variables for the reported results with the function of the newly transplanted organ.

The authors defined primary outcome of hypersensitivity reactions, need for reintubation, hypoxemia, residual neuromuscular blockade, and pneumonia as these could be attributed to the SGX complex persisting in circulation until dialysis is initiated. Although five instances of the primary outcome occurred (3 re-intubations and 2 hypoxemic patients), the authors did not feel that SGX definitively contributed to the complications. While not definitive, this work led the authors to conclude that SGX could be considered to antagonize the neuromuscular blockade in patients with ESRD.

After reading this <u>article</u>, would you use SGX in patients with ESRD?

RESPOND TO THE POLL

